surmount-1 trial tirzepatide non-diabetic obesity weight loss for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURMOUNT-1: Adults achieve weight loss

Pancreatitis rare but serious

They can appear as dots, lines, cobwebs, or other shapes but are most noticeable against plain, bright backgrounds such as a white wall or a clear sky

Many users still achieve excellent weight loss at moderate doses

These include: Nausea the most frequently reported adverse effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive) Abdominal discomfort or pain These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or when the dose is increased

Fourth, MR requires stringent assumptions, i.e., the genetic variants are associated with the exposure, no confounders of the associations of the genetic variants with the outcomes exist, and the genetic variants are not associated with the outcomes other than via affecting the relevant exposure (no pleiotropy) [17]

They matter here because patients and clinics often group them under regenerative scalp treatments